Captaru
  • Grants
  • Volunteers
  • Community
  • Pricing
  • About
    Who We AreOur PartnersJobs
  • Transparency
  • Blog
  • Contact
Captaru Logo

Starting from what we can do and think, our strength is bringing our own and third-party social projects to life.

proyectos@captaru.org
CAPTARU
  • ABOUT US
  • PROJECTS
  • Grant management
  • NGO platform
  • EU funding
  • TRANSPARENCY
  • CONTACT
FOLLOW US
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
Preferred source on Google
JOIN OUR NEWSLETTER AND NEVER MISS AN OPPORTUNITY
Legal NoticeDisclaimerCookie PolicyPrivacy StatementSubscription Terms

Fundación Plaza de Castilla, CIF G84070945, registered at Serrano Anguita 13, 28004 Madrid.

CAPTARU IS A PROJECT DEVELOPED WITH PASSION BY FUNDACIÓN PLAZA DE CASTILLA © 2026 ALL RIGHTS RESERVED

Back to list
Start a proposal with Captaru
🇺🇸GRANTS_GOVOPENGRANT130 days left

NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)

🏛 GRANTS_GOV · 📍 US

Total budget

Not specified

OPENING

Aug 13, 2024

CLOSING

Feb 11, 2027

Category

Education / Health

Description

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorders (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of genomic variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include genomics analysis at the circuit level and the application of neuroscience to genomics studies. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.

Official source

View official source ↗

Eligible beneficiaries

  • Independent school districts
  • Public housing authorities/Indian housing authorities
  • Private institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Public and State controlled institutions of higher education
  • City or township governments
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Native American tribal governments (Federally recognized)
  • State governments
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Small businesses
  • Special district governments
  • For profit organizations other than small businesses

Related calls

  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
  • Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
See all open grants